The MOBILE RCT [14] found that, compared with SMBG, rtCGM resulted in a greater HbA1c reduction (MD −4 mmol/mol [–0.4 pp]), improved TIR and decreased time above range (TAR) and TBR in a type 2 diabetes population treated with basal insulin (p<0.05 for all). The gene discussed is INS; the disease is type 2 diabetes mellitus.